<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hepatic regenerative macronodules observed in <z:hpo ids='HP_0001394'>hepatic cirrhosis</z:hpo> are sensitive to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Lenalidomide is a thalidomide analog used for the treatment of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, with pleiotropic activities including induction of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, inhibition of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and broad immunomodulatory effects </plain></SENT>
<SENT sid="2" pm="."><plain>It has been approved by the Food and Drug Administration (FDA) in the United States and by the European Medicines Agency (EMEA) in 2007 for the use in combination with <z:chebi fb="0" ids="41879">dexamethasone</z:chebi> in the treatment of relapsed or refractory <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>We report a unique observation, which strongly suggests the role of Lenalidomide in hepatic regenerative macronodules infarction </plain></SENT>
</text></document>